Columbia Laboratories' Molecular Profiles to Develop Topical & Oral Psoriasis Products for Telormedix

- Pharmaceutical formulation development and manufacturing services provider Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., CBRX has been selected as the formulation development partner for a major pan-European collaborative project. The UK-based company has been chosen by clinical stage biopharmaceutical company Telormedix SA (Telormedix) to develop both topical and solid dosage formulations for the use in the treatment of psoriasis. The project, operating under the acronym PAT (Psoriasis Anti-inflammatory Treatment), will involve other consortium partners Biopta, Midatech Biogune and the University Hospital Zurich. Telormedix raised funding from the European Eurostars Programme to coordinate this international research project for one of its promising drug candidates, See full press release